FDA Drug Recalls

Recalls / Class I

Class ID-0120-2021

Class I— FDA's most serious classification, issued when there is a reasonable probability that use of or exposure to the drug will cause serious adverse health consequences or death.

Product

Dexmedetomidine HCl in 0.9% Sodium Chloride Injection, 200 mcg / 50 mL (4 mcg / mL), 50 mL Single Dose Bottle, Rx only, Fresenius Kabi, Lake Zurich, IL 60047, NDC 63323-671-05

Brand name
Dexmedetomidine Hydrochloride
Generic name
Dexmedetomidine Hydrochloride
Active ingredient
Dexmedetomidine Hydrochloride
Route
Intravenous
NDC
63323-671
FDA application
ANDA208129
Affected lot / code info
Lot #: 6123925

Why it was recalled

Cross Contamination with other products: trace amounts of lidocaine

Recalling firm

Firm
Fresenius Kabi USA, LLC
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
3 Corporate Dr, N/A, Lake Zurich, Illinois 60047-8930

Distribution

Quantity
13,525 bottles
Distribution pattern
USA Nationwide

Timeline

Recall initiated
2020-11-17
FDA classified
2020-12-08
Posted by FDA
2020-12-16
Terminated
2022-09-12
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-0120-2021. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.

Class I recall: Dexmedetomidine Hydrochloride · FDA Drug Recalls